Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the AB 13 82 (genetically Modified Animals) topic
No spam. Unsubscribe anytime.
Committee advances ban on sale of animals genetically modified for cosmetic traits; GloFish exempted
Summary
The committee passed AB 13 82 (Castillo) to the Judiciary Committee. The bill would bar sale of animals genetically modified solely for cosmetic traits, with the author and supporters citing shelter overpopulation and ethical concerns; opponents, including pet‑industry representatives, urged science‑based regulatory review and warned of legal uncertainty for FDA‑ or state‑approved ornamental species.
The Assembly Business and Professions Committee voted to send AB 13 82 (Castillo) to the Committee on Judiciary. The bill would prohibit the sale of animals whose genetic modification is carried out for cosmetic or novelty purposes, while expressly exempting biomedical research.
Assemblymember Castillo told the committee the measure targets commercial novelty modifications and is not intended to inhibit genetic research that benefits society. "The language is explicitly curated to target animals genetically modified for the sole purpose of sale," Castillo said.
Supporters, including Nicholas Sackett of Social Compassion in Legislation and Karen Lang of the California Animal Welfare Association, said the bill would help avoid adding medically complex novelty animals to already overburdened shelters. Sackett cited state shelter statistics and said novelty pets could exacerbate the fiscal and welfare burden on public and nonprofit rescue systems.
Alyssa Miller Hurley, vice president for government relations at the Pet Advocacy Network, testified in opposition and urged the committee to rely on existing science and state regulatory review. She noted GloFish and other transgenic aquarium fish have undergone federal and state review and warned that the bill’s civil penalties (described in testimony as $5,000 per animal) and ambiguous language could harm small, regulated ornamental‑fish businesses.
Members asked clarifying questions about exemptions and regulatory overlap; several members said the bill is narrowly tailored and acknowledged the exemption for FDA‑ or state‑approved products. The committee voted to pass AB 13 82 to the Committee on Judiciary.
What’s next: AB 13 82 will be reviewed by the Judiciary Committee, where members may examine legal definitions, regulatory preemption, and penalty language.
